CAJ | 학술논문

背景与目的:细胞因子诱导的肿瘤杀伤细胞(cytokine-induced killer cells,CIK cells)对肝癌细胞具有较强的抗肿瘤活性,联合CIK细胞疗法是否能够进一步消除介入治疗后的残留癌细胞或降低介入治疗后的复发率仍需进一步研究证实.本研究拟评价肝动脉栓塞化疗(transcatheter arterial chemoembolization,TACE)联合CIK细胞疗法对肝癌的疗效.方法:146例有TACE指征而无手术切除指征的原发性肝癌患者被分为TACE联合CIK组(72例)及单纯TACE组(74例),并接受相应治疗.主要评价终点指标为无进展生存率和总生存率.结果:联合组半年、1年、2年无进展生存率分别为72.2%、40.4%、25.3%,单纯TACE组分别为34.8%、7.7%、2.6%.两组中位疾病进展时间分别是11个月(95%CI,8～14个月)和5个月(95%CI,4～7个月).联合组半年、1年、2年总生存率分别为90.3%、71.9%、62.4%,单纯TACE组分别为74.6%、42.8%、18.8%.两组中位生存期分别是31个月(95%CI,27～35个月)和10个月(95%CI.7～13个月).TACE次数、ECOG评分状态和CIK细胞免疫治疗是独立的预后因素.结论:TACE联合CIK细胞免疫治疗能明显提高TACE的疗效,在延长无进展生存和总生存期方面起着重要作用.
배경여목적:세포인자유도적종류살상세포(cytokine-induced killer cells,CIK cells)대간암세포구유교강적항종류활성,연합CIK세포요법시부능구진일보소제개입치료후적잔류암세포혹강저개입치료후적복발솔잉수진일보연구증실.본연구의평개간동맥전새화료(transcatheter arterial chemoembolization,TACE)연합CIK세포요법대간암적료효.방법:146례유TACE지정이무수술절제지정적원발성간암환자피분위TACE연합CIK조(72례)급단순TACE조(74례),병접수상응치료.주요평개종점지표위무진전생존솔화총생존솔.결과:연합조반년、1년、2년무진전생존솔분별위72.2%、40.4%、25.3%,단순TACE조분별위34.8%、7.7%、2.6%.량조중위질병진전시간분별시11개월(95%CI,8～14개월)화5개월(95%CI,4～7개월).연합조반년、1년、2년총생존솔분별위90.3%、71.9%、62.4%,단순TACE조분별위74.6%、42.8%、18.8%.량조중위생존기분별시31개월(95%CI,27～35개월)화10개월(95%CI.7～13개월).TACE차수、ECOG평분상태화CIK세포면역치료시독립적예후인소.결론:TACE연합CIK세포면역치료능명현제고TACE적료효,재연장무진전생존화총생존기방면기착중요작용.
Background and Objective:Cytokine-induced killer(CIK)cells have high anti-tumor activity for hepatocellular carcinoma(HCC).Whether CIK cell therapy can eradicate residual cancer cells and prevent or postpone tumor relapse after transcatheter arterial chemoembolization(TACE)should be testified.This study was to evaluate the efficacy of CIK cell therapy combined with TACE on HCC.Methods:A total of 146 consecutive patients with unresectable HCC were divided into combination group (72 patients trealted with CIK cell therapy combined with TACE) and TACE group(74 patients treated only with TACE).The progression-free survival(PFS)and overall survival(OS)were analyzed.Results:The 6-month,1-year,and 2-year PFS rales were 72.2%, 40.4%, 25.3%in combination group, and 34.8%,7.7%,2.6%in TACE group.The median time to progression was 11 months[95%confidence interval(CI),8-1 4 months]in combination group and 5 months(95% CI,4-7 months)in TACE group.The estimated 6-month, 1-year, and 2-year OS rates were 90.3%, 71.9%. 62.4%in combination group,and 74.6%,42.8%,18.8%in TACE group.The median OS was 31 months(95%CI,27-35 months)in combination group and 10 months(95% CI,7-13 months)in TACE group.The times of TACE,ECOG performance status, and CIK cell therapy were independent prognostic factors for PFS and OS.Conclusion:Adjuvant immunotherapy with CIK cells could greatly improve the efficacy of TACE on HCC,and plays an important role in prolonging the PFS and OS of HCC patients after TACE.